Pharmaceuticals

Alzheimer’s Disease Treatment Market Forecast Highlighting Key Drivers And Expansion Potential

April 28, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Alzheimer’s Disease Treatment Market Expected To Change From 2026 To 2030?

The market for alzheimer’s disease treatment has experienced robust expansion in recent years. It is projected to expand from $6.94 billion in 2025 to $7.37 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.2%. Historical growth in this sector is primarily driven by factors such as the increasing prevalence of alzheimer’s disease, an aging global population, the limited availability of effective therapies, growing awareness about cognitive disorders, and the rising healthcare infrastructure supporting neurological diseases.

The alzheimer’s disease treatment market size is projected to experience substantial growth in the coming years, reaching $9.51 billion by 2030 with a compound annual growth rate (CAGR) of 6.6%. This anticipated growth during the forecast period is attributable to several factors, including the development of beta-amyloid targeted immunotherapies, the expansion of monoclonal antibody treatments, the rising adoption of combination therapies, an increase in home care and telemedicine services for alzheimer’s patients, and greater investment in early detection and diagnostic biomarkers. Key trends anticipated in the same period involve a surge in investment towards immunotherapy and monoclonal antibodies, a greater uptake of combination drugs that target multiple pathways, an expansion of early diagnosis and biomarker-based treatment approaches, an intensified focus on preserving cognitive function and enhancing memory, and the integration of home-based care alongside remote patient monitoring for alzheimer’s.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3409&type=smp

Which Factors Are Influencing The Growth Of The Alzheimer’s Disease Treatment Market?

The expansion of the Alzheimer’s disease treatment market is anticipated to be fostered by government initiatives. A government initiative refers to a strategic plan or action implemented by a government to address a specific problem or issue, which can receive funding from various channels, including taxes, grants, and donations. In the context of Alzheimer’s disease treatment, these governmental efforts are directed towards research projects, particularly clinical trials for novel drugs and therapies. As an illustration, the American Medical Association, a US-based Professional organizations, stated in April 2025 that U.S. health expenditure in 2023 climbed by 7.5% to $4.9 trillion, equating to $14,570 per capita, thereby surpassing the 4.6% increase observed in 2022. Consequently, government initiatives serve as a primary catalyst for the growth experienced in the Alzheimer’s disease treatment market.

Which Segment Categories Are Included In The Alzheimer’s Disease Treatment Market Segment Analysis?

The alzheimer’s disease treatment market covered in this report is segmented –

1) By Drug Class: Cholinergic, Memantine, Combined Drug, AChE inhibitors, Immunoglobulins

2) By Drug Type: Cholinesterase Inhibitors, NMDA Receptor Antagonists

Subsegments:

1) By Cholinergic: Donepezil, Galantamine, Rivastigmine

2) By Memantine: Memantine Hydrochloride, Extended-Release Memantine

3) By Combined Drug: Donepezil and Memantine Combination

4) By AChE Inhibitors: Tacrine, Physical Inhibitors

5) By Immunoglobulins: IVIG (Intravenous Immunoglobulin), Monoclonal Antibodies

What Trends Are Transforming The Alzheimer’s Disease Treatment Market?

Leading firms within the Alzheimer’s disease treatment market are prioritizing regulatory authorizations to secure a competitive advantage and improve their product portfolios. These authorizations represent official permission from governmental bodies, including the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), allowing a product to be commercially distributed and sold. As an illustration, in July 2024, Eli Lilly and Company, a US-based pharmaceutical firm, secured FDA approval for its Alzheimer’s therapy, Kisunla (donanemab-azbt). This treatment is prescribed for adults diagnosed with early symptomatic Alzheimer’s disease, encompassing individuals with mild cognitive impairment and mild dementia. This medication is administered through a monthly intravenous infusion and has shown effectiveness in decelerating the disease’s advancement during clinical trials. This approval underscores its potential influence, given that it was granted Fast Track, Priority Review, and Breakthrough Therapy designations.

Who Are The Active Companies Shaping The Alzheimer’s Disease Treatment Market?

Major companies operating in the alzheimer’s disease treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Merck Sharp & Dohme Corp., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., UCB S.A., Eisai Co. Ltd., Forest Laboratories LLC, Ono Pharmaceutical Co. Ltd., H. Lundbeck A/S, Allergan plc, Luye Pharma Group, Avanir Pharmaceuticals Inc., Denali Therapeutics Inc., Athira Pharma Inc., ProMIS Neurosciences Inc., AC Immune SA, vTv Therapeutics Inc., AB Science SA, TauRx Pharmaceuticals Ltd., Alzheon Inc.

Get The Full Alzheimer’s Disease Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/alzheimer-disease-treatment-global-market-report

Which Region Is The Top Contributor To The Alzheimer’s Disease Treatment Market By Share?

North America is the largest region in the Alzheimer’s disease treatment market in 2025. Middle East is expected to be the fastest growing region in the Alzheimer’s disease treatment market share during the forecast period. The regions covered in the alzheimer’s disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Alzheimer’s Disease Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/alzheimer-disease-treatment-global-market-report

Browse Through More Reports Similar to the Global Alzheimer’s Disease Treatment Market 2026, By The Business Research Company

Neurodegenerative Disorder Therapeutic Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutic-global-market-report

Alzheimer Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/alzheimer-disease-treatment-global-market-report

Medical Foods Market Report 2026

https://www.thebusinessresearchcompany.com/report/medical-foods-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795